UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

Kymera Therapeutics (NASDAQ:KYMR) had its price target decreased by UBS Group from $80.00 to $74.00 in a research report released on Monday morning, Benzinga reports. UBS Group currently has a buy rating on the stock.

Several other research firms have also recently weighed in on KYMR. B. Riley lifted their price target on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday, July 9th. Truist Financial reaffirmed a “buy” rating and issued a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a report on Friday, November 1st. Wells Fargo & Company lifted their price objective on Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Oppenheimer lifted their price objective on Kymera Therapeutics from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Friday, September 27th. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Monday, September 9th. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $51.21.

Kymera Therapeutics Stock Up 3.8 %

KYMR opened at $49.48 on Monday. The stock has a market cap of $3.20 billion, a price-to-earnings ratio of -21.15 and a beta of 2.21. The business has a 50 day moving average of $46.96 and a 200-day moving average of $40.93. Kymera Therapeutics has a 12-month low of $13.85 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million during the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm’s revenue for the quarter was down 20.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.90) EPS. As a group, analysts expect that Kymera Therapeutics will post -2.83 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Pamela Esposito sold 13,500 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. 15.82% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD grew its position in shares of Kymera Therapeutics by 18.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after buying an additional 996,300 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Kymera Therapeutics by 19.2% in the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company’s stock valued at $191,635,000 after purchasing an additional 769,486 shares during the period. Avoro Capital Advisors LLC lifted its stake in shares of Kymera Therapeutics by 3.0% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,888,888 shares of the company’s stock valued at $156,333,000 after purchasing an additional 113,888 shares during the period. Artal Group S.A. lifted its stake in shares of Kymera Therapeutics by 19.6% in the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company’s stock valued at $121,691,000 after purchasing an additional 496,400 shares during the period. Finally, Jennison Associates LLC acquired a new position in shares of Kymera Therapeutics in the 1st quarter valued at about $17,122,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.